MentiNova, Inc
MentiNova's primary strategy is to use L-DOPA, the drug that is currently clinically approved for another indication and repurpose it for the treatment of L-Dopa Induced Dyskinesia in patients with Parkinson's disease.
1
Funding Rounds
$500.0k
Money raised
Overview
MentiNova's primary strategy is to use L-DOPA, the drug that is currently clinically approved for another indication and repurpose it for the treatment of L-Dopa Induced Dyskinesia in patients with Parkinson's disease.
- Website:
Funding series
Funding Series Analysis
The company MentiNova, Inc has raised a total of $500k in funding over 1 rounds.
Key Insights:
- MentiNova, Inc funding round, January 2013: $500k
MentiNova, Inc funding round, January 2013
$500k